Erythroid response to treatment with G‐CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model

No abstract is available for this paper.

• Publication year

  1997

• Venue

  British Journal of Haematology

• Publication date

  1997-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1365-2141.1997.4013211.xPMID 9375752
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin and α-tocopherol

  1996cited by this paper
• Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy.

  1996cited by this paper
• Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy.

  1996cited by this paper
• Efficacy of erythropoietin in the myelodysplastic syndromes: a meta‐analysis of 205 patients from 17 studies

  1995cited by this paper
• Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response.

  1995cited by this paper
• The use of r‐HuEpo in the treatment of anaemia related to myelodysplasia (MDS)

  1995cited by this paper
• Failure of combination therapy with recombinant granulocyte colony-stimulating factor and erythropoietin in myelodyspplastic syndromes

  1994cited by this paper
• Granulocyte colony-stimulating factor and erythropoietin for the anemia of myelodysplastic syndromes: a real improvement with respect to erythropoietin alone?

  1994cited by this paper
• Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin.

  1993cited by this paper
• Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.

  1993cited by this paper
• A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes.

  1993cited by this paper
• A predictive model for the clinical response to low dose ara‐C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia

  1992cited by this paper
• Treatment of myelodysplastic syndromes with hemopoietic growth factors.

  1992cited by this paper
• Differential and synergistic effects of human granulocyte-macrophage colony-stimulating factor and human granulocyte colony-stimulating factor on hematopoiesis in human long-term marrow cultures.

  1991cited by this paper
• Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor.

  1990cited by this paper
• Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients.

  1989cited by this paper
• Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases

  1987cited by this paper
• Myelodysplastic syndromes: a scoring system with prognostic significance

  1985cited by this paper
• Statistical and Knowledge‐Based Approaches to Clinical Decision‐Support Systems, with an Application in Gastroenterology

  1984cited by this paper
• Proposals for the classification of the myelodysplastic syndromes

  1982cited by this paper

• Navigating the dynamic landscape of lower-risk MDS: Advances and emerging insights.

  2025cites this paper
• Recombinant human erythropoietin plus all-trans retinoic acid and testosterone undecanoate for the treatment of anemia in patients with lower-risk myelodysplastic syndromes: a multicenter, single-arm, prospective trial

  2025cites this paper
• Novel agents and evolving strategies for anemia management in lower-risk myelodysplastic syndromes

  2025cites this paper
• IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score.

  2025cites this paper
• Low‐risk MDS—A spotlight on precision medicine for SF3B1‐mutated patients

  2025cites this paper
• Advances and Challenges in the Management of Myelodysplastic Syndromes

  2025cites this paper
• Berries vs. Disease: Revenge of the Phytochemicals

  2024cites this paper
• A Systematic Literature Review of Predictors of Erythropoiesis-Stimulating Agent Failure in Lower-Risk Myelodysplastic Syndromes

  2024cites this paper
• Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities

  2024cites this paper
• Bewegung in die richtige Richtung: Diagnostik und Therapie myelodysplastischer Neoplasien

  2024cites this paper
• An internet-based educational algorithm for the work-up, diagnosis and management of patients with myelodysplastic syndromes from the Canadian Consortium on MDS

  2023cites this paper
• Raising the bar for lower-risk myelodysplastic syndromes

  2023cites this paper
• Eltrombopag in Lower-Risk Myelodysplastic Syndrome: Revival of Its Use in Thrombocytopenia.

  2023cites this paper
• New Approaches to Myelodysplastic Syndrome Treatment

  2022cites this paper
• Risk

  2022cites this paper
• Lower‐risk myelodysplastic syndromes: Current treatment options for anemia

  2022cites this paper
• A Pilot Clinical Study to Investigate the Hypomethylating Properties of Freeze-dried Black Raspberries in Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasm

  2022cites this paper
• Treatment of lower-risk myelodysplastic syndrome

  2022cites this paper
• Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin.

  2021cites this paper
• Development of luspatercept to treat ineffective erythropoiesis.

  2021influential citation
• Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine

  2021cites this paper
• More general incorporation of hemoglobin level into response criteria for myelodysplastic syndrome and acute myeloid leukemia with increase in minimum red cell transfusion levels

  2021cites this paper
• Switching to an alternative recombinant erythropoietin agent in patients with myelodysplastic syndromes: a second honeymoon?

  2021cites this paper
• Risk

  2021cites this paper
• Senescent Mesenchymal Stem Cells in Myelodysplastic Syndrome: Functional Alterations, Molecular Mechanisms, and Therapeutic Strategies

  2021cites this paper
• Management of the Older Patient with Myelodysplastic Syndrome

  2021influential citation
• Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes

  2021cites this paper
• Düşük Risk Myelodisplastik Sendromda Darbepoetin ve Koloni Uyarıcı Faktör Tedavisinin Anemi Üzerine Etkisi

  2020cites this paper
• Risk

  2020cites this paper
• Current Standard of Care in Patients with Myelodysplastic Syndromes and Future Perspectives

  2020cites this paper
• Myelo-deception: Luspatercept & TGF-Beta ligand traps in myeloid diseases & anemia.

  2020cites this paper
• Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile

  2020cites this paper
• Real-World Costs of Azacitidine Treatment in Patients With Higher-Risk Myelodysplastic Syndromes/Low Blast-Count Acute Myeloid Leukemia.

  2020cites this paper
• Myelodysplastische Syndrome (MDS)

  2020cites this paper
• Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the ‘real-world’

  2020cites this paper
• Myelodysplastic Syndromes

  2020cites this paper
• Risk

  2020cites this paper
• Setting Fire to ESA and EMA Resistance: New Targeted Treatment Options in Lower Risk Myelodysplastic Syndromes

  2019cites this paper
• Novel therapies in low- and high-risk myelodysplastic syndrome

  2019cites this paper
• The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion

  2019cites this paper
• Risk

  2019cites this paper
• Clinical Benefit‐Risk Profile of Lenalidomide in Patients With Lower‐risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial

  2019cites this paper
• Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocols.

  2019cites this paper
• Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score‐matched analysis

  2019cites this paper
• Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes

  2019cites this paper
• Efficacy of granulocyte colony stimulating factor in combination with erythropoiesis stimulating agents for treatment of anemia in patients with lower risk myelodysplastic syndromes: A systematic review.

  2019cites this paper
• The fraction of CD117/c‐KIT‐expressing erythroid precursors predicts ESA response in low‐risk myelodysplastic syndromes

  2019cites this paper
• Current and evolving understanding of atypical chronic myeloid leukemia.

  2019cites this paper
• Part 3: Myelodysplastic syndromes—Treatment of low-risk patients without the 5q deletion

  2018cites this paper
• Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes.

  2018cites this paper
• A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS

  2018cites this paper
• Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

  2018cites this paper
• Diagnosis, management and response criteria of iron overload in myelodysplastic syndromes (MDS): updated recommendations of the Austrian MDS platform

  2018cites this paper
• Supportive Therapie in der geriatrischen Onkologie

  2018cites this paper
• 骨髄異形成症候群を発症した血液透析患者へ, 短時間作用型ESAとエポエチンベータペゴル併用投与により, 輸血依存性を離脱した1症例

  2018cites this paper
• Azacitidine in the ‘real‐world’: an evaluation of 1101 higher‐risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada

  2018cites this paper
• Managing anaemia in bone marrow failure syndromes

  2018cites this paper
• Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents

  2018cites this paper
• Recent advances in the cellular and molecular understanding of myelodysplastic syndromes: implications for new therapeutic approaches.

  2018cites this paper
• Current treatment algorithm for the management of lower-risk MDS.

  2017cites this paper
• ITACA: A new validated international erythropoietic stimulating agent‐response score that further refines the predictive power of previous scoring systems

  2017cites this paper
• Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.

  2017cites this paper
• Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS).

  2017cites this paper
• Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

  2017cites this paper
• Clinical use of ESAs in Low-Risk Myelodysplastic Syndromes

  2017cites this paper
• Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS.

  2017cites this paper
• First-line Therapeutic Strategies for Myelodysplastic Syndromes.

  2017cites this paper
• Management of Adult Patients with Myelodysplastic Syndromes

  2017cites this paper
• The True Face of Myelodysplastic Syndromes and Related Neoplasms in the Netherlands: Studies based on population-based registries

  2016cites this paper
• Treatment of low-risk myelodysplastic syndromes.

  2016cites this paper
• Myelofibrosis: an update on drug therapy in 2016

  2016influential citation
• Granulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes.

  2016cites this paper
• Response to erythropoietic‐stimulating agents in patients with chronic myelomonocytic leukemia

  2016influential citation
• APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis

  2016cites this paper
• Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.

  2016influential citation
• [Serum Erythropoietin as Prognostic Marker in Myelodysplastic Syndromes].

  2015cites this paper
• Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management

  2015cites this paper
• The myelodysplastic syndromes: the era of understanding

  2015cites this paper
• Thrombopoiesis‐stimulating agents and myelodysplastic syndromes

  2015cites this paper
• Darbepoetin alfa for anemia with myelodysplastic syndrome

  2015cites this paper
• Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response.

  2015cites this paper
• A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes

  2015cites this paper
• Anemia as the Main Manifestation of Myelodysplastic Syndromes.

  2015cites this paper
• [Current treatment strategies for myelodysplastic syndromes].

  2015cites this paper
• Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial

  2014cites this paper
• Development and validation of a model to predict platelet response to romiplostim in patients with lower‐risk myelodysplastic syndromes

  2014influential citation
• Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients

  2014cites this paper
• Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy

  2014cites this paper
• Erythrocytic Mobilization Enhanced by the Granulocyte Colony-Stimulating Factor Is Associated with Reduced Anthrax-Lethal-Toxin-Induced Mortality in Mice

  2014cites this paper
• KRasG12D-evoked leukemogenesis does not require β-catenin

  2014cites this paper
• Resuscitating a Dying Marrow: the Role of Hematopoietic Growth Factors

  2014cites this paper
• Update on the pharmacotherapy for myelodysplastic syndromes

  2014cites this paper
• Treatment of patients with myelodysplastic syndromes

  2014cites this paper
• Myelodysplastic syndromes.

  2014cites this paper
• Verifying Hellström-Lindberg score as predictive tool for response to erythropoietin therapy according to the “International Working Group” criteria, in anemic patients affected by myelodysplastic syndrome: a monocentric experience

  2013cites this paper
• Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents

  2013cites this paper
• Myelodysplastic syndromes: what do hospitalists need to know?

  2013cites this paper
• recommendations from the European LeukemiaNet Diagnosis and treatment of primary myelodysplastic syndromes in adults

  2013cites this paper
• High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM

  2013cites this paper
• Distribution of serum erythropoietin levels in lower risk myelodysplastic syndrome cases with anemia

  2013cites this paper